Peter Anastasiou

Peter Anastasiou serves as Capsida’s Chief Executive Officer and member of the board of directors. He has over 30 years of experience managing multifunctional and diverse organizations, leading them to achieve ambitious shared goals. During his tenure as Capsida’s CEO, he led the expansion of the company’s partnership with AbbVie into a new therapeutic area and created a new partnership with Eli Lilly & Co, raising a total of $125 million upfront and the potential for >$1.2 billion in milestones and royalties between the two deals. Before Capsida, Mr. Anastasiou served as an Executive Vice President, member of the global executive committee, and President of North American operations at Lundbeck. As President of Lundbeck’s U.S. and Canadian operations, Mr. Anastasiou led as many as 1,200 employees, achieved annual net revenues of >$1.5 billion with margins of >60%, played a pivotal role in developing, launching and/or commercializing multiple products (Rexulti, Trintellix, Abilify Maintena, Vyepti, Northera, Onfi, Sabril, Xenazine), and built the company’s cross-functional capabilities. Prior to Lundbeck, he held management roles at Neuronetics, Inc. (NeuroStar TMS Therapy), Bristol-Myers Squibb Company (Abilify), and Eli Lilly & Company (Cymbalta). Mr. Anastasiou represented Lundbeck on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) for more than four years and currently serves on the global advisory board for the Healthcare Businesswomen’s Association. He was named the 2019 HBA Honorable Mentor and one of the 2020 PharmaVOICE 100. He holds an M.B.A. from the Kelley School of Business at Indiana University and a B.A. in economics and management from Albion College (MI).